How To Use ZOMETA® | Patient Case Study: Multiple Myeloma
Home

Videos
View videos on bone
metastases and the ZOMETA
mechanism of action

Learn more about the ZOMETA(zoledronic acid) mechanism of action

 
European Summary of Product Characteristics
For non-U.S. Healthcare Professionals: Get information about ZOMETA and its product characteristics

Learn more about ZOMETA product characteristics 		 
ZOMETA Patient Case Study: Multiple Myeloma ZOMETA is the current standard of care for the prevention of skeletal-related events (SREs)

ZOMETA® Multiple Myeloma Patient Case Study – Marie Marie T.
  • Aged 62 years
  • Lives and works on a family farm
  • Enjoys walking her dogs with her husband
Medical Profile The clinical question Reasons for ZOMETA How to use ZOMETA References
Page  1 2 3

In patients like Marie, the vicious cycle of bone destruction is ongoing

  • Osteoclasts and osteoblasts continually weaken bone in a vicious cycle of destruction7,8
ZOMETA®: Osteoclasts and osteoblasts continually weaken bone in SREs

Because bone is constantly being attacked, ZOMETA® must be dosed
every 3 to 4 weeks7,9


Page  1 2 3


 

Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US flag at the top right corner of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.

About ZOMETA | ZOMETA Patient Case Studies | ZOMETA Dosing & Administration | ZOMETA Safety & Tolerability | ZOMETA Clinical News | ZOMETA For Your Patients | Professional Resource Center
ZOMETA Around the World

About Novartis OncologySiteMapContactPrivacy
 


Use of this website is subject to our Terms of Use
© 2010 Novartis AG.